



30
YEARS

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

February 1, 2024

- Presentations to be webcast on www.exelixis.com -

ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 1, 2024-- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences in February:

- Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Thursday, February 8 in New York City.
- Oppenheimer 34th Annual Healthcare Life Sciences Conference: Exelixis is scheduled to present virtually at 12:40 p.m. ET / 9:40 a.m. PT on Tuesday, February 13.

To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow [@ExelixisInc](https://twitter.com/ExelixisInc) on X (Twitter), like [Exelixis, Inc.](https://www.facebook.com/Exelixis.Inc) on Facebook and follow [Exelixis](https://www.linkedin.com/company/exelixis) on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240201568516/en/): <https://www.businesswire.com/news/home/20240201568516/en/>

Investors Contact:

Varant Shirvanian
Associate Director, Investor Relations
Exelixis, Inc.
650-837-8194
vshirvanian@exelixis.com

Media Contact:

Hal Mackins
For Exelixis, Inc.
415-994-0040
hal@torchcommunications.com

Source: Exelixis, Inc.